Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis

Dec 13, 2021

Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition

Dec 9, 2021

Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results

Nov 10, 2021

Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update

Nov 3, 2021

Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin

Oct 26, 2021

Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors

Oct 14, 2021

Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer

Sep 27, 2021

Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition

Sep 17, 2021

Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results

Aug 11, 2021

Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update

Aug 4, 2021